These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 30523754)

  • 1. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
    Burstein HJ; Lacchetti C; Griggs JJ
    J Oncol Pract; 2019 Feb; 15(2):106-107. PubMed ID: 30523754
    [No Abstract]   [Full Text] [Related]  

  • 2. Prolactin and endocrine therapy resistance in breast cancer: The next potential hope for breast cancer treatment.
    Li Y; Kong X; Xuan L; Wang Z; Huang YH
    J Cell Mol Med; 2021 Nov; 25(22):10327-10348. PubMed ID: 34651424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Balancing the risks and benefits of extended adjuvant endocrine therapy.
    Jhaveri KL
    Clin Adv Hematol Oncol; 2019 Feb; 17(2):105-108. PubMed ID: 30845113
    [No Abstract]   [Full Text] [Related]  

  • 4. Case Report: Long-Term Response to Pembrolizumab Combined With Endocrine Therapy in Metastatic Breast Cancer Patients With Hormone Receptor Expression.
    Wu D; Tang S; Ye R; Li D; Gu D; Chen R; Zhang H; Sun J; Chen Z
    Front Immunol; 2021; 12():610149. PubMed ID: 33692787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
    Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
    Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool.
    Chia YH; Ellis MJ; Ma CX
    Br J Cancer; 2010 Sep; 103(6):759-64. PubMed ID: 20700118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmaceutical therapy of breast cancer].
    Láng I; Kahán Z; Pintér T; Dank M; Boér K; Pajkos G; Faluhelyi Z; Pikó B; Eckhardt S; Horváth Z
    Magy Onkol; 2010 Sep; 54(3):237-54. PubMed ID: 20870601
    [No Abstract]   [Full Text] [Related]  

  • 8. Optimal regimen for treatment-naive hormone receptor-positive HER-2 negative metastatic breast cancer.
    Bilgin B; Şendur MA; Hızal M; Akıncı MB; Dede DŞ; Yalçın B
    Future Oncol; 2019 Jan; 15(2):105-107. PubMed ID: 30484708
    [No Abstract]   [Full Text] [Related]  

  • 9. Survival improvement in hormone-responsive young breast cancer patients with endocrine therapy.
    Yoon TI; Hwang UK; Kim ET; Lee S; Sohn G; Ko BS; Lee JW; Son BH; Kim S; Ahn SH; Kim HJ
    Breast Cancer Res Treat; 2017 Sep; 165(2):311-320. PubMed ID: 28601930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression Summary.
    Burstein HJ; Lacchetti C; Griggs JJ
    J Oncol Pract; 2016 Apr; 12(4):390-3. PubMed ID: 26931400
    [No Abstract]   [Full Text] [Related]  

  • 11. Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer.
    Ohno S
    Clin Breast Cancer; 2016 Aug; 16(4):238-46. PubMed ID: 27151773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer update.
    Kuter I
    Oncologist; 2000; 5(4):285-92. PubMed ID: 10964995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended adjuvant chemotherapy in endocrine non-responsive disease.
    Colleoni M; Munzone E
    Breast; 2013 Aug; 22 Suppl 2():S161-4. PubMed ID: 24074780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update.
    Giordano SH; Freedman RA; Somerfield MR;
    J Clin Oncol; 2022 Jan; 40(3):307-309. PubMed ID: 34878801
    [No Abstract]   [Full Text] [Related]  

  • 15. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
    Jankowitz RC; McGuire KP; Davidson NE
    Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of molecular tools for extended adjuvant endocrine therapy decisions in early breast cancer.
    Ribnikar D; Bedard PL
    Future Oncol; 2017 Dec; 13(30):2733-2736. PubMed ID: 29168649
    [No Abstract]   [Full Text] [Related]  

  • 17. Adjuvant chemotherapy in luminal breast cancers.
    Lim E; Winer EP
    Breast; 2011 Oct; 20 Suppl 3():S128-31. PubMed ID: 22015279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Adjuvant chemotherapy of early stage breast cancer].
    Boér K
    Orv Hetil; 2010 Feb; 151(9):344-53. PubMed ID: 20159750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global View of Candidate Therapeutic Target Genes in Hormone-Responsive Breast Cancer.
    Salvati A; Gigantino V; Nassa G; Mirici Cappa V; Ventola GM; Cracas DGC; Mastrocinque R; Rizzo F; Tarallo R; Weisz A; Giurato G
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
    ; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD
    J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.